← Oncology Approval Tracker

FDA DECISION ·

Palbociclib tablets

palbociclib · Synthon Pharmaceuticals

First generic approvalFirst genericBreast cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

First generic 75 mg, 100 mg and 125 mg tablets for adults with HR-positive, HER2-negative advanced or metastatic breast cancer. Use with an aromatase inhibitor initially or with fulvestrant after progression on endocrine therapy.

LAMPGEN ANALYSIS

Why it matters

The FDA approved a generic tablet for the labeled endocrine-combination settings. FDA's signed initial approval letter is dated August 2023. The agency's 2024 listing references the same application and strengths.

What research teams should watch

Distinguish the approval date from market availability and verify whether a tablet or capsule is prescribed.

PRIMARY RECORDS

Sources